Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945695 | 0.86 | NR1H2 (0.40) | NR1H2NR1H3 | |
| SCHEMBL21945733 | 0.86 | CYP1A2 (0.38) | POLB | |
| SCHEMBL21945135 | 0.86 | ADORA2A (0.42) | MAPTPOLBL3MBTL1 | |
| SCHEMBL26070403 | 0.85 | GPR84 (0.35) | MAOBNR1H2NR1H3MAOAL3MBTL1 | |
| SCHEMBL21944776 | 0.85 | MRGPRX4 (0.48) | MRGPRX4 | |
| SCHEMBL26070378 | 0.84 | MRGPRX4 (0.43) | L3MBTL1MRGPRX4 | |
| SCHEMBL21944766 | 0.81 | PRMT6 (0.33) | POLB | |
| SCHEMBL18003993 | 0.80 | NR4A2 (0.50) | MAOBNR4A2NR1H2NR1H3MAPT | |
| SCHEMBL26070417 | 0.80 | CYP11B1 (0.34) | NR1H3MAPTPOLBMRGPRX4NR1H4 | |
| SCHEMBL26070427 | 0.79 | TACR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MAOB 3664/4885NR4A2 2048/4885NR1H2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.